Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN)

AUTHORS

Mahshid Naseri Karimvand 1 , 2 , Hadi Kalantar 3 , 4 , Mohammad Javad Khodayar ORCID 3 , 4 , *

1 Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Faculty of Allied Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

How to Cite: Naseri Karimvand M, Kalantar H, Khodayar M J. Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN), Jundishapur J Nat Pharm Prod. 2020 ; 15(4):e81969. doi: 10.5812/jjnpp.81969.

ARTICLE INFORMATION

Jundishapur Journal of Natural Pharmaceutical Products: 15 (4); e81969
Published Online: December 5, 2020
Article Type: Research Article
Received: July 11, 2018
Revised: May 20, 2019
Accepted: May 26, 2019
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Polyphenolic compounds have anti-proliferative effects and can trigger apoptosis in cancer cells. Ferulic acid is excessively found in various herbal products and fruits. Ferulic acid plays a role in the treatment of neurodegenerative diseases, cancer, diabetes, cardiovascular disease, inflammation, and bacterial and viral infections.

Objectives: The purpose of this study was to evaluate the anticancer effect of ferulic acid on renal carcinoma cells (ACHN).

Methods: To assess the anti-proliferative effect of ferulic acid, the renal carcinoma cell line (ACHN) was treated with different ferulic acid concentrations (10, 20, 40, 80, and 160 μM) for 24, 48, and 72 hours. Cell viability was measured using the MTT assay. The apoptosis of cancer cells was evaluated by flow cytometry and real-time PCR.

Results: The IC50 of ferulic acid against ACHN cells was determined to be 30 μM at 72 hours with the MTT assay. The treatment of cells with ferulic acid concentrations of 30 and 60 μM caused a significant increase in the apoptosis index. The Bcl-2 gene expression level was significantly lower in the treated group than in the control group, and the Bax gene expression level was significantly higher in the treated group than in the control group (P < 0.001).

Conclusions: The results of this study showed the apoptotic activity of ferulic acid against ACHN cells. These results can be helpful in the better understanding of the anticancer mechanism of ferulic acid, suggesting this substance as an alternative drug or in combination with conventional chemical treatments for cancer treatment.

1. Background

Cancer is a complex disease, which is incurable in some cases (1). Renal Cell Carcinoma (RCC) usually occurs in people over 40 years and accounts for 3% of all cancers. The incidence of this cancer is two times higher in men than in women. Obesity, overweight, and tobacco use are factors that increase the risk of developing kidney tumors. People working in the heavy metal industry, petrochemical industry, and metal mines are at an elevated risk of developing kidney tumors compared to other people in the community. Several studies have been conducted to explore a new diet rich in phenolic compounds to eliminate this malignancy (2).

Chemotherapy is one of the therapeutic techniques for cancer patients (3). Although the main goal of chemotherapy is to remove tumor cells, chemotherapeutic drugs often penetrate healthy cells and destroy them. In addition, many side effects appear after they are taken, including fatigue, nausea, vomiting, diarrhea, mucositis (inflammation of the oral mucosa), pain, rash, infection, and headache (4). Researchers believe that nutritional factors, herbs, and their effective compounds may affect chemotherapy and thus help in treating cancer. Various natural compounds can improve the effectiveness of chemotherapy by decreasing the resistance to chemotherapeutic drugs, reducing or eliminating the side effects of these drugs (5). On the other hand, one of the greatest limitations of anticancer drugs is the resistance of cancer cells to chemotherapeutic drugs that can be caused by the intrinsic resistance of the tumor to the drug or resistance obtained during chemotherapy and may act to select resistant cells from heterozygous cells. As a result, the treatment process becomes more difficult with the growth of resistant cells (6).

Herbal medicines have been considered nowadays because of lacking the side effects of chemical drugs (7). The polyphenolic compounds have been recognized as anticancer agents. The presence of phenolic compounds in various diets reduces the risk of diseases such as cancer and diabetes (8). There is a strong relationship between the type of diet and its impact on cancer. Hence, diet is an important risk factor for the onset of cancer (9). The polyphenolic compounds have anti-proliferative effects and can trigger apoptosis in cancer cells. Based on molecular studies of phenolic compounds in cancer cells, it has been found that these compounds, through increased intracellular calcium, can induce apoptosis in cancer cells, resulting in reduced tumor size and increased chance of recovery in these patients (10).

Ferulic acid is a phenolic compound found in the cell wall of plants such as rice and barley and the seeds of fruits such as apples, oranges, and grapes. Studies have shown that this compound has antioxidant, anti-inflammatory, anti-diabetic, anti-apoptotic, anti-aging, neuroprotective, and anti-tumor effects (11). The induction of apoptosis is one of the functional mechanisms of anticancer drugs that cause the death of cancer cells.

2. Objectives

Given the scope of studies on herbal treatments and the importance of phenolic compounds in the treatment and prevention of cancer, it seems essential to understand the molecular mechanisms of natural compounds in the treatment of RCC. Therefore, the current study aimed to investigate the anticancer and apoptotic effects of ferulic acid on the renal carcinoma cell line of ACHN.

3. Methods

3.1. Materials

The human renal carcinoma cell line (ACHN) was provided by the Pasteur Institute of Iran. Ferulic acid was purchased from Sigma Company (St. Louis, USA). Annexin V-FLUOS Staining Kit and Bax/ Bcl-2 Expression Assay Kit were purchased from QIAGEN Co.

3.2. Cell Culture

The ACHN cells were cultured in RPMI 1640 culture medium enriched with 10% Fetal Bovine Serum (FBS), 100 U/ml of penicillin, and 100 μg/ml of streptomycin under controlled conditions of 37˚C and 5% CO2. The medium was removed three times a week. Trypsin was used to harvest the cells. When at least 80% of the cells reached sufficient growth in the flask, they were separated from the flask bottom by trypsin and centrifuged at 1,500 rpm for 10 min. The cell deposition was suspended in 2 cc of culture medium, and the cell viability percentage was determined by mixing an equal ratio of trypan blue. Cells with viability percentages of higher than 90% were used for the next experiments. The protocols of this study were confirmed by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1396.796).

3.3. Studying Ferulic Acid Cytotoxicity by MTT Assay

The MTT assay was used to evaluate the proliferation of ACHN cells. This test is a rapid and sensitive method for evaluating cytotoxicity in vitro. To this end, 24 hours before ferulic acid treatment, 5,000 cells were seeded in each well of a 96-well plate. Then, various concentrations of ferulic acid (10, 20, 40, 80, and 160 μM) were added to the wells and remained for different periods (24, 48, and 72 hours) in culture conditions. After the given time elapsed, the supernatant was discarded, and 200 μl of the MTT dye was added and incubated for 4 h at 37˚C. Next, 150 μl of dimethyl sulfoxide (DMSO) was added and shaken with a shaker for 10 min at room temperature. The absorbance was read at a wavelength of 570 nm by an ELISA reader. The results were analyzed using the GraphPad Prism version 6.0 software, and the concentration causing 50% removal of viable cells was considered as IC50.

3.4. Analysis of Apoptosis by Flow Cytometry

To determine the percentage of apoptotic cells in treated cells and make a comparison with the control cell group, cell staining was done with the Annexin V, and Propidium Iodide (PI) dyes using the commercial Annexin V-FLUOS Staining Kit. Thus, cells (5×105) were treated with 30 and 60 μM of ferulic acid concentrations for 72 h and then trypsinized and rinsed with sterile Phosphate-buffered Saline (PBS). The sediment resulting from centrifugation of cells was added to 100 μl of the binding buffer in a microtube. Next, 5 μl of PI and 5 μl of Annexin V were added to the contents of the microtube. The contents and the tube were gently mixed. In the next step, the samples were incubated at room temperature (25˚C) for 15 min in the dark. After that, 400 μl of the binding buffer was added to each tube, and cellular analysis was immediately done by FACScan flow cytometry (Becton Dickinson, America).

Data were analyzed using the device software. The positive points in the two-dimensional curve were divided into four regions from Q1 to Q4, including Annexin V-/PI- (left lower quadrant) for viable cells, Annexin V+/PI- (lower right quadrant) for early apoptotic cells, Annexin V+/PI+ (upper right quadrant) for late apoptotic cells, and Annexin V-/PI+ (upper left quadrant) for necrotic cells. The percentage of cells in each area was calculated by FCS Express software and reported as the percentage to determine the effects of ferulic acid on inducing apoptosis or necrosis.

3.5. Evaluation of Bax and Bcl-2 Gene Expression Using Real-Time PCR

Cells (5×105) treated with 30 and 60 μM concentrations of ferulic acid underwent the real-time PCR. The RNA extraction was performed with the RNase-free DNase kit. The next step was the cDNA synthesis using the cDNA Synthesis Kit (Thermo Scientific Co.). The real-time PCR process was performed in a final volume of 10 μl. Primers, enzymatic mixtures, and DEPC-treated water first reached the ambient temperature and were prepared after short centrifugation. Strip tubes (20-μl tubes connected to each other specific for the real-time PCR) were placed on ice under ventilation and added with 5 μl of 2X Master Mix, 3 μl of DEPC-treated water, and 0.5 μl of each primer. The cDNA was then melted onto the ice, shortly centrifuged, and added to each strip tube. Finally, the samples were transferred into the real-time PCR device. The experiment was carried out after temperature and 45-cycle setting. The primers used in this study are presented in Table 1.

Table 1. Primer Sequences and Lengths Used in the Study
PrimerSequencePrimer Length
Bax F5'-AGAGGATGATTGCCGCCGT-3'19
Bax R5'-CAACCACCCTGGTCTTGGATC-3'21
Bcl-2 F5'-TTGGCCCCCGTTGCTT-3'16
Bcl-2 R5'-CGGTTATCGTACCCCGTTCTC-3'21
GAPDH F5'-TTCTATAAATTGAGCCCGCAGCC-3'23
GAPDH R5'-CCGTTGACTCCGACCTTCAC-3'20

3.6. Statistical Analysis

In this study, the one-way ANOVA test with P < 0.05 was used to compare between all groups and the t-test to compare between two groups. The changes in Bcl-2 and Bax gene expression were calculated by comparing with GAPDH gene expression using the Pfaffl method.

4. Results

4.1. MTT Assay

In the MTT assay, the IC50 values of ferulic acid against the ACHN cell line were 39.5, 34.3, and 30 μM at 24, 48, and 72 hours, respectively. Hence, the minimum IC50 for this drug, which was achieved within 72 hours, was used as the IC50 for subsequent experiments. Furthermore, the effects of ferulic acid at the doubled concentration of IC50 (60 μM) were evaluated on the ACHN cell line. The results are shown in Figure 1.

Figure 1. Calculation of ferulic acid IC50 against ACHN cell line

4.2. Flow Cytometry

The flow cytometry with Annexin V-FITC/PI staining was used to evaluate the post-treatment apoptosis. The control group, unexposed to ferulic acid, showed 99.4% viable cells, 0.45% total early and late apoptotic cells, and 0.15% necrotic cells. The group treated with 30 μM of ferulic acid showed 16.65% viable cells, 79.71% total early and late apoptotic cells, and 3.64% necrotic cells. The group treated with 60 μM of ferulic acid showed 13.06% viable cells, 79.72% total early and late apoptotic cells, and 7.21% necrotic cells. The results are shown in Figure 2. The Bcl-2 protein family plays a key role in apoptosis, and pro-apoptotic and anti-activity levels are important in controlling apoptosis in cells. The study confirmed the role of Bcl-2 in inducing apoptosis caused by ferulic acid. The effects of ferulic acid on the expression of the Bax and Bcl-2 genes were investigated using real-time PCR in the ACHN cell line. The expression of the Bax and Bcl-2 genes are shown in Figure 3.

Figure 2. Apoptotic cell determination of ACHN cancer cells at different concentrations of ferulic acid by flow cytometry and Annexin V/PI staining, Group A: Control group (without ferulic acid treatment), Group B: Treatment with 30 μM of ferulic acid, Group C: Treatment with 60 μM of ferulic acid, Q1: Viable cells (Annexin V-/PI-), Q2: Early apoptotic cells (Annexin V-/PI+), Q3: Late apoptotic cells and early necrotic cells (Annexin V+/PI+), Q4: Necrotic cells (Annexin V-/ PI+), Analyzing the Expression of apoptosis-associated Genes
Figure 3. Effects of ferulic acid on the expression of Bax and Bcl-2 genes in ferulic acid-treated cancer cells. *P<0.001 versus control in Bax gene expression (A) and Bcl-2 gene expression (B).

5. Discussion

Cancer is one of the main public health problems in developed and developing countries. According to the World Health Organization, 21 million new cases of cancer and 11.5 million deaths from cancer will occur annually around the world by 2030 (12). Renal cell carcinoma is one of the most common cancers, especially in developed countries. They are tumors that originate from epithelial cells of the renal tubules and account for over 90% of kidney tumors. Renal cell carcinoma is the eighth malignancy among the most common cancers in America (13). The induction of apoptosis or programmed cell death is characterized by certain features such as chromatin condensation, DNA fragmentation, membrane buckling, caspase activity, and phosphatidylserine transfer from the inner to outer layers of the plasma membrane, which is one of the useful tools for cancer treatment (14).

Chemotherapeutic drugs can induce apoptosis, often due to DNA damage and oxidative stress. Oxidative stress is a condition in which the imbalance comes from the production of free radicals and antioxidant defense systems (15). Among chemotherapeutic drugs, it will be beneficial to use compounds that act with the oxidative stress system inside the cancerous cell, such as flavonoid family derivatives. In addition, many studies have indicated that some of these flavonoids have specific applications, especially for the treatment of certain cancers. Many of these compounds can also be effective in overall cancer treatment processes through the mechanisms of inhibiting DNA synthesis, modifying ROS production, regulating the cell cycle, and repairing apoptotic pathways (16). Flavonoids are known as potent antioxidants that protect cells from oxygen-derived free radicals (16). They prevent mutations and initiate carcinogenesis. Recently, it has been observed that they can induce apoptosis in cancerous cells (17). Therefore, further studies are needed to identify the molecular mechanism of naturally occurring anticancer compounds, especially plant-derived compounds.

Evidence suggests that ferulic acid can act as an antitumor agent in various human cancers. It has been shown that ferulic acid inhibits 7,12-Dimethylbenz [a] anthracene-induced (DMBA) in breast and skin cancers through anti-genotoxic and antioxidant features, regulating the effects in phase II detoxification cascades and reducing buccal cancer through decreasing the expression of PCNA and Cyclin D1 (18). In addition, it has been reported that ferulic acid, curcumin, chlorogenic acid, and caffeic acid can inhibit skin cancer induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in rats (19). Ferulic acid is expected to reduce ROS (11); however, since the cancerous cell has an acidic region (20), ferulic acid is unable to play a role as an antioxidant but acts mostly as a pro-oxidant (21). Studies show that ferulic acid, along with radiotherapy, can reduce the antioxidant status and increase ROS, lipid peroxidation, and DNA damage (21). One of the reasons for increasing ROS by ferulic acid may be attributed to its effect on P53 activity. Ferulic acid has been reported to inhibit the change in the function of P53 in buccal carcinoma and has a beneficial effect in treating this type of cancer (22). As known, P53 is a tumor suppressor (23), which also plays a role in regulating the expression of many pro-oxidant and antioxidant genes, including catalase, superoxide dismutase, and glutathione peroxidase. Increasing its proper functioning can lead to a loss of redox hemostasis (24) and induce oxidative stress (25).

The results of this study indicated that ferulic acid can prevent renal carcinoma cell line proliferation in a concentration-dependent manner. Ferulic acid has been reported to induce apoptosis in non-small cell lung cancer (NSCLC) by increasing P53, Bax, caspase 3, and GADD45 (26), as well as in the Caco-2 colon cancer cell line, causing a delay in the synthesis phase of the cell cycle and an increase in the expression of CEP2, CETN3, and RABGAP1 genes, which control DNA damage in the cell cycle of the S phase (27). In the present study, it was found that the anticancer effect and apoptotic induction property of ferulic acid can be due to an increase in the expression of the Bax gene and a decrease in the expression of the Bcl-2 gene, which encodes the apoptotic proteins. It has been proven that ferulic acid induces apoptosis through increasing the expression of the Bax and caspase 3 genes and decreasing the expression of the Bcl-2 gene (28).

The safety of ferulic acid should be considered because ferulic acid has a nephrodamaging effect in chronic use (29). It has also been demonstrated that ferulic acid can reduce multi-drug resistance (MDR) to paclitaxel in cancer cell line KB. This effect is induced by decreasing the expression of the ABCB1 and p-glycoprotein genes, inducing apoptosis through increasing the P53 expression, increasing the Bax/Bcl-2 expression ratio, and increasing CDKN1A, ultimately leading to the enhancement of cell cycle arrest in the G2/M phase along with paclitaxel (30). Besides, Bcl-2 is the first known gene associated with apoptosis, which plays a role in tumor formation (31). The members of the Bcl-2 family in mammals can control the internal pathway of apoptosis by inhibiting the release of cytochrome C and other mitochondrial membrane proteins into cytosol. Some members of the Bcl-2 family, including Bax, act as pro-apoptotic agents and proceed to apoptosis by increasing the release of mitochondrial proteins. However, some other members, such as Bcl-2, act as anti-apoptotic factors and cause the inhibitory release of mitochondrial proteins. Indeed, these two groups restrain each other's actions. The balance between their activities usually determines the presence or absence of cell apoptotic induction (31).

In the current study, the treatment of cancer cells with different concentrations of ferulic acid resulted in cell apoptosis as confirmed by flow cytometry. The flow cytometry studies with Annexin V staining in ferulic acid-treated cells indicated the apoptosis and introduction into the apoptotic phase compared to the control group (without ferulic acid treatment). It was also shown that apoptosis is a major cause of cell death and growth inhibition in predicted concentrations. However, a very small percentage of cells had necrosis, but this rate was not significant compared to the percentage of apoptotic cells. The findings of this study revealed that ferulic acid can precede renal carcinoma cells towards apoptosis and prevent their proliferation.

5.1. Conclusion

According to the results obtained in the present study, ferulic acid has apoptotic effects against ACHN cancer cells. These findings can be helpful in the better understanding of ferulic acid anticancer mechanisms, suggesting its use as an alternative or complementary drug for cancer therapy.

Footnotes

References

  • 1.

    Dalkic E, Wang X, Wright N, Chan C. Cancer-drug associations: a complex system. PLoS One. 2010;5(4). e10031. doi: 10.1371/journal.pone.0010031. [PubMed: 20368808]. [PubMed Central: PMC2848862].

  • 2.

    Keaney CM, Springate JE. Cancer and the kidney. Adolesc Med Clin. 2005;16(1):121-48. doi: 10.1016/j.admecli.2004.09.012. [PubMed: 15844387].

  • 3.

    Liu F. Mechanisms of Chemotherapeutic Drug Resistance in Cancer Therapy—A Quick Review. Taiwanese Journal of Obstetrics and Gynecology. 2009;48(3):239-44. doi: 10.1016/s1028-4559(09)60296-5.

  • 4.

    Nicolson GL. Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res. 2005;11(3):139-44. doi: 10.1007/BF02893390. [PubMed: 16195767].

  • 5.

    Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012;2012:282570. doi: 10.1155/2012/282570. [PubMed: 23320169]. [PubMed Central: PMC3539428].

  • 6.

    Rahman M, Hasan MR. Cancer Metabolism and Drug Resistance. Metabolites. 2015;5(4):571-600. doi: 10.3390/metabo5040571. [PubMed: 26437434]. [PubMed Central: PMC4693186].

  • 7.

    Park EJ, Pezzuto JM. Botanicals in cancer chemoprevention. Cancer Metastasis Rev. 2002;21(3-4):231-55. doi: 10.1023/a:1021254725842. [PubMed: 12549763].

  • 8.

    Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. 3 Biotech. 2013;3(6):439-59. doi: 10.1007/s13205-013-0117-5. [PubMed: 28324424]. [PubMed Central: PMC3824783].

  • 9.

    Sak K. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev. 2014;8(16):122-46. doi: 10.4103/0973-7847.134247. [PubMed: 25125885]. [PubMed Central: PMC4127821].

  • 10.

    Chirumbolo S, Bjorklund G, Lysiuk R, Vella A, Lenchyk L, Upyr T. Targeting Cancer with Phytochemicals via Their Fine Tuning of the Cell Survival Signaling Pathways. Int J Mol Sci. 2018;19(11). doi: 10.3390/ijms19113568. [PubMed: 30424557]. [PubMed Central: PMC6274856].

  • 11.

    Srinivasan M, Sudheer AR, Menon VP. Ferulic Acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr. 2007;40(2):92-100. doi: 10.3164/jcbn.40.92. [PubMed: 18188410]. [PubMed Central: PMC2127228].

  • 12.

    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11). e442. doi: 10.1371/journal.pmed.0030442. [PubMed: 17132052]. [PubMed Central: PMC1664601].

  • 13.

    de Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Inflammation and Cancer. 816. Springer; 2014. p. 197-234.

  • 14.

    Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87. doi: 10.1186/1756-9966-30-87. [PubMed: 21943236]. [PubMed Central: PMC3197541].

  • 15.

    Yokoyama C, Sueyoshi Y, Ema M, Mori Y, Takaishi K, Hisatomi H. Induction of oxidative stress by anticancer drugs in the presence and absence of cells. Oncol Lett. 2017;14(5):6066-70. doi: 10.3892/ol.2017.6931. [PubMed: 29113247]. [PubMed Central: PMC5661396].

  • 16.

    M Estrela L. Natural Polyphenols and Apoptosis Induction in Cancer Therapy. Journal of Carcinogenesis & Mutagenesis. 2013. doi: 10.4172/2157-2518.s6-004.

  • 17.

    Mollakhalili Meybodi N, Mortazavian AM, Bahadori Monfared A, Sohrabvandi S, Aghaei Meybodi F. Phytochemicals in cancer prevention: a review of the evidence. Iranian Journal of Cancer Prevention. 2017;10(1).

  • 18.

    Alias LM, Manoharan S, Vellaichamy L, Balakrishnan S, Ramachandran CR. Protective effect of ferulic acid on 7,12-dimethylbenz[a]anthracene-induced skin carcinogenesis in Swiss albino mice. Exp Toxicol Pathol. 2009;61(3):205-14. doi: 10.1016/j.etp.2008.09.001. [PubMed: 18845425].

  • 19.

    Huang M, Smart RC, Wong C, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer research. 1988;48(21):5941-6.

  • 20.

    Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer research. 1989;49(16):4373-84.

  • 21.

    Karthikeyan S, Kanimozhi G, Prasad NR, Mahalakshmi R. Radiosensitizing effect of ferulic acid on human cervical carcinoma cells in vitro. Toxicol In Vitro. 2011;25(7):1366-75. doi: 10.1016/j.tiv.2011.05.007. [PubMed: 21600977].

  • 22.

    Balakrishnan S, Manoharan S, Alias LM, Nirmal MR. Effect of curcumin and ferulic acid on modulation of expression pattern of p53 and bcl-2 proteins in 7, 12-dimethylbenz [] anthracene-induced hamster buccal pouch carcinogenesis. IJBB. 2010;47(1):7-12.

  • 23.

    Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell. 2004;116:S67-70. doi: 10.1016/s0092-8674(04)00036-4.

  • 24.

    Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008;10(8):1343-74. doi: 10.1089/ars.2007.1957. [PubMed: 18522489]. [PubMed Central: PMC2932530].

  • 25.

    Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7(2):97-110. doi: 10.1016/j.drup.2004.01.004. [PubMed: 15158766].

  • 26.

    Bandugula VR, N RP. 2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells. Tumour Biol. 2013;34(1):251-9. doi: 10.1007/s13277-012-0545-6. [PubMed: 23065571].

  • 27.

    Janicke B, Hegardt C, Krogh M, Onning G, Akesson B, Cirenajwis HM, et al. The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer. 2011;63(4):611-22. doi: 10.1080/01635581.2011.538486. [PubMed: 21500097].

  • 28.

    Wang T, Gong X, Jiang R, Li H, Du W, Kuang G. Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl Res. 2016;8(2):968-80. [PubMed: 27158383]. [PubMed Central: PMC4846940].

  • 29.

    Peng CC, Hsieh CL, Wang HE, Chung JY, Chen KC, Peng RY. Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease. Clin Nutr. 2012;31(3):405-14. doi: 10.1016/j.clnu.2011.11.003. [PubMed: 22154988].

  • 30.

    Muthusamy G, Balupillai A, Ramasamy K, Shanmugam M, Gunaseelan S, Mary B, et al. Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines. Eur J Pharmacol. 2016;786:194-203. doi: 10.1016/j.ejphar.2016.05.023. [PubMed: 27262378].

  • 31.

    Zeidooni L, Rezaei M, Hashemi Tabar M. Gamma Tocopherol and Lovastatin Additively Induced Apoptosis in Human Colorectal Carcinoma Cell Line (HT29). Jundishapur J Nat Pharm Prod. 2012;7(4):153-8. [PubMed: 24624174]. [PubMed Central: PMC3941870].

  • Copyright © 2020, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: